(Q35640641)

English

Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer

scientific article published on December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Nancy A Dawson

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Susan F Slovin

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

62 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

102-118

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

DNA vaccines: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Induction of a cytotoxic T lymphocyte (CTL) response to plasmid DNA delivered via Lipodine liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Study of the expression and function of the tumour-associated antigen CaMBr1 in small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Breast cancer immunotherapy: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Enhancement of DNA vaccine potency using conventional aluminum adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Gene therapy approaches in urologic oncology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Cyclooxygenase-2: a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Inhibition of cyclooxygenase-2 gene expression by p53.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Role of cyclooxygenases in angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Many actions of cyclooxygenase-2 in cellular dynamics and in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Sulindac inhibits activation of the NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Expression of cyclooxygenase-2 in prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Non-steroidal anti-inflammatory drugs and prostate cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Inhibition of nuclear factor-kappaB by a nitro-derivative of flurbiprofen: a possible mechanism for antiinflammatory and antiproliferative effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

The role of vitamin D in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Vitamin D receptor: a potential target for intervention

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24‐dihydroxyvitamin D2

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Vitamin D-related therapies in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus fusion gene.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.027

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.UROLOGY.2003.10.027

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35640641&oldid=2049305452"